MedDataX Logo

Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

NCT ID: NCT00157976

Last Updated: 2005-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

660 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Macular Degeneration AMD Visual Acuity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Photrex (rostaporfin)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Miravant Pharmaceuticals

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wendy J. Snyder, PhD

Role: STUDY_DIRECTOR

Miravant Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Multiple Investigators

Sofia, , Bulgaria

Site Status RECRUITING

Multiple Investigators

Brno-Bohunice, Olomouc, Praha, , Czechia

Site Status RECRUITING

Multiple Investigators

Warsaw, Bydgoszcz, Lubin, , Poland

Site Status RECRUITING

Multiple Investigators

Bucharest, , Romania

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Bulgaria Czechia Poland Romania

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Miravant Pharmaceuticals

Role: CONTACT

Phone: 1-800-685-2959

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRVT-920101-OPH005

Identifier Type: -

Identifier Source: org_study_id